Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model

Antiviral Research

Volumn 88, Issue 3, 2010, Pages 276-280

  Bantia, Shanta ^a   Kellogg, Debra ^a   Parker, Cynthia D ^a   Babu, Y S ^a  

^a BIOCRYST PHARMACEUTICALS INC   (United States)

Author keywords

Combination therapy; Influenza; Intramuscular; Mouse model; Peramivir; Rimantadine

Indexed keywords

PERAMIVIR; RIMANTADINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; IN VIVO STUDY; INFLUENZA A (H3N2); MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION;

ANIMALS; ANTIVIRAL AGENTS; CYCLOPENTANES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; GUANIDINES; INFLUENZA A VIRUS, H3N2 SUBTYPE; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RIMANTADINE; SURVIVAL RATE; WEIGHT LOSS;

INFLUENZA A VIRUS; MUS;

EID: 78650232558     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.09.020     Document Type: Article

References (24)

1. Babu Y.S., Chand P., Bantia S., Kotian P.L., Dehghani A., El-Kattan Y., Lin T., Hutchison T.L., Elliot A.J., Parker C.D., Ananth S.L., Horn L.L., Laver G.W., Montgomery J.A. BCX-1812 (RWJ - 270201): discovery of a novel, highly potent, orally active and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 2000, 43:3482-3486.
2. Bantia S., Parker C.D., Ananth S.L., Horn L.L., Andries K., Chand P., Kotian P.L., Dehghani A., El-Kattan Y., Lin T., Hutchison T.L., Montgomery J.A., Kellogg D.L., Babu Y.S. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 2001, 45:1162-1167.
3. Bantia S., Arnold C.S., Parker C.D., Upshaw R., Chand P. Anti influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 2006, 69:39-45.
4. Belshe R.B., Smith M.H., Hall C.B., Betts R., Hay A.J. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 1988, 62:1508-1512.
5. Boltz D.A., Ilyushina N.A., Arnold C.S., Babu Y.S., Webster R.G., Govorkova E.A. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral Res. 2008, 80:150-157.
6. Correia V., de Andrade H.R., Santos L.A., Lackenby A., Zambon M. Antiviral drug profile of seasonal influenza viruses circulating in Portugal from 2004/2005 to 2008/2009 winter seasons. Antiviral Res. 2010, 86:128-136.
7. Drusano G.L., Preston S.L., Smee D., Bush K., Bailey K., Sidwell R.W. Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing. Antimicrob. Agents Chemother. 2001, 45:2115-2118.
8. Galabov A.S., Simeonova L., Gegova G. Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice. Antivir. Chem. Chemother. 2006, 17:251-258.
9. Govorkova E.A., Leneva I.A., Goloubeva O.G., Bush K., Webster R.G. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 2001, 45:2723-2732.
10. Ilyushina N.A., Bovin N.V., Webster R.G., Govorkova E.A. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res. 2006, 70:121-131.
11. Ilyushina N.A., Hay A., Yilmaz N., Boon A.C., Webster R.G., Govorkova E.A. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob. Agents Chemother. 2008, 52:3889-3897.
12. Ison M.G., Gnann J.W., Nagy-Agren S., Treannor J., Paya C., Steigbigel R., Elliott M., Weiss H.L., Hayden F.G. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir. Ther. 2003, 8:183-190. NIAID Collaborative Antiviral Study Group.
13. Ison M.G., McGeer A.J., Hui D.S., Clezy K., O'Neil B., Flynt A., Elder J., Simon T.J., Alexander W.J. Safety and efficacy of multiple-day treatment with intravenous peramivir or oral oseltamivir in hospitalized adults with acute influenza. XI International Symposium on Respiratory Viral Infections 2009, Oral abstract.
14. Johansson B.E., Grajower B., Kilbourne E.D. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine 1993, 11:1037-1039.
15. Kobayashi M., Kodama M., Yoshida R., Sato A., Yamano Y., Isoda N., Sadoda Y., Kida H. Inhibitory effect of peramivir (S-021812, BCX-1812) against highly pathogenic avian influenza viruses. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009) 2009, Abstract V-1064.
16. Kohno S., Yen M.Y., Cheong H.J., et al. V-537a-Single-intravenous peramivir vs. oral oseltamivir to treat acute, uncomplicated influenza in the outpatient setting: a phase III randomized, double-blind trial. V-537a. ICAAC 2009 2009, Abstract V-537a.
17. Mendel D.B., Tai C.Y., Escarpe P.A., Li W., Sidwell R.W., Huffman J.H., Sweet C., Jakeman K.J., Merson J., Lacy S.A., Lew W., Williams M.A., Zhang L., Chen M.S., Bischofberger N., Kim C.U. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. 1998, 42:640-646.
18. Prichard M.N., Shipman C. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 1990, 14:181-205.
19. Sidwell R.W., Smee D.F., Huffman J.H., Barnard D.L., Bailey K.W., Morrey J.D., Babu Y.S. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RWJ-270201. Antimicrob. Agents Chemother. 2001, 45:749-757.
20. Smee D.F., Bailey K.W., Morrison A.C., Sidwell R.W. Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 2002, 48:88-93.
21. Smee D.F., Hurst B.L., Wong M.H., Bailey K.W., Morrey J.D. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob. Agents Chemother. 2009, 53:2120-2128.
22. Smee D.F., Hurst B.L., Wong M.H., Bailey K.W., Tarbert E.B., Morrey J.D., Furuta Y. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob. Agents Chemother. 2010, 54:126-133.
23. Ujike M., Shimabukuro K., Mochizuki K., Obuchi M., Kageyama T., Shirakura M., Kishida N., Yamashita K., Horikawa H., Kato Y., Fujita N., Tashiro M., Odagiri T. Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan. Emerg. Infect. Dis. 2010, 16:926-935.
24. Wang C., Takeuchi K., Pinto L.H., Lamb R.A. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J. Virol. 1993, 67:5585-5594.